According to the OPPI, launching a new drug in India is delayed by up to four years, compared to markets like the US and the European Union. This affects the launch of innovative and significant products in India. The lobby represents pharma giants including Novartis, Roche, AstraZeneca, Sanofi and Merck. The group blames the delay on complex clinical trial regulations.
The Organisation of Pharmaceutical Producers of India (OPPI) has appointed Anil Matai as its director general. Matai has extensive experience in the pharmaceutical industry, having worked with companies such as Novartis India, GSK India, and Global Pharma. He has also served on the boards of several healthcare companies.
information comes out. they have to accepmevet some of the guidance early on , even if it was well intended, was ill advised and to think thatand th they were squashing peopleey who went out and did their own research, found their own answers and just put it out there and say that you didn t have you don t have the right to do that i rign a countrhty, e the first amendment. but they re not going to try tat tr hide it because they don t care becausy e they think they ree rs righteous in doing this. doing they believe in their power this anmore than our rights. r you know, the theknow the disinformation board that they floated and then they saw that america wasn t goin board s accept it is really in effect, although they don t have it out there openly with what s her name singing mary poppins. oppi. but they basically have a disinformation board. dothey bas have di you think that s t constitutional, jessica?t i m not surhise the courts , i guess, will play it out if it- ever gets tak